Drug Interactions in Parkinson’s Disease: Safety of Pharmacotherapy for Arterial Hypertension

被引：7
作者：
Bitner A. [1 ]
Zalewski P. [1 ]
Klawe J.J. [1 ]
Newton J.L. [2 ]
机构：
[1] Chair and Department of Hygiene and Epidemiology, The Ludwik Rydygier Collegium Medicum in Bydgoszcz, The Nicolaus Copernicus University in Toruń, M. Sklodowskiej-Curie 9, Bydgoszcz
[2] Institute for Ageing and Health, The Medical School, Newcastle University, Framlington Place, Newcastle-upon-Tyne
来源：
Drugs - Real World Outcomes | 2015年 / 2卷 / 1期
关键词：
Levodopa; Orthostatic Hypotension; Amantadine; Selegiline; Cabergoline;
D O I：
10.1007/s40801-015-0008-7
中图分类号：
学科分类号：
摘要：
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder of the central nervous system, observed in patients aged older than 50 years. In this study, we review interactions between therapies used in PD and selected antihypertensive agents. Moreover, in view of the lack of evidence-based recommendations regarding the pharmacotherapy of arterial hypertension in PD patients, we propose effective and safe therapeutic algorithms for these two coexisting conditions. Method: We used the “Drug interactions” database affiliated with the Ministry of Health, which allows for the identification of interactions between compared active compounds. The database is updated on a monthly basis and all data are consistent with current legislation. For information about interactions, we additionally added data from the British National Formulary, a joint publication of the British Medical Association and the Royal Pharmaceutical Society of Great Britain. In this analysis, we also used data from Micromedex®, Cerner Multum™, Wolters Kluwer™, Lexicomp® and Stockley’s®. We analysed the potential interactions between antihypertensive and anti-parkinsonian agents included in respective guidelines on the pharmacotherapy of these conditions. Results: Our analysis revealed the lack of clinically relevant interactions between preparations of levodopa and benserazide (used for the treatment of PD) and angiotensin-converting enzyme inhibitors, antagonists of AT1 receptor for angiotensin II or antagonists of β-adrenoreceptors (β-adrenolytics). Conclusion: To avoid major drug-to-drug interactions, patients receiving preparations of levodopa and benserazide should be prescribed angiotensin-converting enzyme inhibitors, antagonists of AT1 receptor for angiotensin II, or antagonists of β-adrenoreceptors (β-adrenolytics) as the first-line agents of antihypertensive treatment. © 2015, The Author(s).
引用
收藏
页码：1 / 12
页数：11
相关论文
共 42 条
[1]  
Dauer W., Przedborski S., Parkinson’s disease: mechanisms and models, Neuron, 39, 6, pp. 889-909, (2003)
[2]  
Goldstein D.S., Dysautonomia in Parkinson’s disease: neurocardiological abnormalities, Lancet Neurol, 2, 11, pp. 669-676, (2003)
[3]  
Goldman J.G., Postuma R., Premotor and nonmotor features of Parkinson’s disease, Curr Opin Neurol, 27, 4, pp. 434-441, (2014)
[4]  
Oka H., Yoshioka M., Onouchi K., Morita M., Mochio S., Suzuki M., Et al., Characteristics of orthostatic hypotension in Parkinson’s disease, Brain, 130, 9, pp. 2425-2432, (2007)
[5]  
Custaud M.A., de Souza Neto E.P., Abry P., Flandrin P., Millet C., Duvareille M., Orthostatic tolerance and spontaneous baroreflex sensitivity in men versus women after 7 days of head-down bed rest, Auton Neurosci, 100, 1-2, pp. 66-76, (2002)
[6]  
Guyenet P.G., The sympathetic control of blood pressure, Nat Rev Neurosci, 7, 5, pp. 335-346, (2006)
[7]  
Berganzo K., Diez-Arrola B., Tijero B., Somme J., Lezcano E., Llorens V., Et al., Nocturnal hypertension and dysautonomia in patients with Parkinson’s disease: are they related?, J Neurol, 260, 7, pp. 1752-1756, (2013)
[8]  
Pavy-Le Traon A., Amarenco G., Duerr S., Kaufmann H., Lahrmann H., Shaftman S.R., The Movement Disorders Task Force review of dysautonomia rating scales in Parkinson’s disease with regard to symptoms of orthostatic hypotension, Mov Disord, 26, 11, pp. 1985-1992, (2011)
[9]  
Senard J.M., Chamontin B., Rascol A., Montastruc J.L., Ambulatory blood pressure in patients with Parkinson’s disease without and with orthostatic hypotension, Clin Auton Res, 2, 2, pp. 99-104, (1992)
[10]  
Qiu C., Hu G., Kivipelto M., Laatikainen T., Antikainen R., Fratiglioni L., Et al., Association of blood pressure and hypertension with the risk of Parkinson disease: the National FINRISK Study, Hypertension, 57, 6, pp. 1094-1100, (2011)
12345